Novartis Kisqali Now First and Only CDK4/6 Inhibitor Indicated in US as First-line Therapy Specifically for Premenopausal Women; and as Initial Therapy with Fulvestrant in Postmenopausal Women

Originally Published by Novartis.

Novartis announced a new approval for Kisqali (ribociclib) from the US Food and Drug Administration (FDA) for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. Kisqali is now the only CDK4/6 inhibitor indicated for use with an aromatase inhibitor for the treatment of pre-, peri- or postmenopausal women in the US, and also is indicated for use in combination with fulvestrant as both first- or second-line therapy in postmenopausal women[1]. FDA reviewed this supplemental New Drug Application (sNDA) under its Real-Time Oncology Review and Assessment Aid pilot programs and approved the application in less than one month after submission.


“Compelling data for Kisqali have led to the broadest first-line indications of any CDK4/6 inhibitor,” said Liz Barrett, CEO, Novartis Oncology. “With this new approval Kisqali has the potential to help even more people in the US live a longer life without progression of disease from this incurable form of breast cancer.”

This approval is based on the pivotal MONALEESA-7 and MONALEESA-3 Phase III clinical trials that demonstrated prolonged progression-free survival (PFS) and improvements as early as eight weeks for Kisqali-based regimens compared to endocrine therapy alone[1]. In MONALEESA-7, Kisqali plus an aromatase inhibitor and goserelin nearly doubled the median PFS compared to an aromatase inhibitor and goserelin alone (27.5 months compared to 13.8 months; HR=0.569; 95% CI: 0.436-0.743) in pre- or perimenopausal women[1]. In MONALEESA-3, Kisqali plus fulvestrant demonstrated a median PFS of 20.5 months compared to 12.8 months for fulvestrant alone (HR=0.593; 95% CI: 0.480-0.732) across the overall population of first-line and second-line postmenopausal women[1].

“These MONALEESA clinical trial program data add to the body of evidence that CDK 4/6 inhibition, in the case of these studies with ribociclib, gives women diagnosed with HR+/HER2- advanced breast cancer an important first-line treatment option,” said Dennis J. Slamon, MD, Director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center. “Based on Phase III trial results that consistently showed clinical benefit, physicians should be encouraged to re-evaluate treatment for advanced breast cancer in the first-line setting.”

Approximately 155,000 people in the US are living with metastatic breast cancer[2]. Up to one-third of patients with early-stage breast cancer will subsequently develop advanced disease, for which there is currently no cure[3]. Advanced breast cancer in premenopausal women is a biologically distinct and more aggressive disease, and it is the leading cause of cancer death in women 20-59 years old[4],[5].

“Premenopausal women diagnosed with advanced breast cancer often face unique social challenges and a poorer prognosis. For the first time in nearly 20 years, we have results from a dedicated clinical trial among these women,” said Jennifer Merschdorf, CEO, Young Survival Coalition. “With this approval, some younger women now have a new therapy indicated specifically for them that may help extend their lives without progression of disease.”

Novartis is committed to providing patients with access to medicines, as well as resources and support to address a range of needs. The Kisqali patient support program is available to help guide eligible patients through the various aspects of getting started on treatment, from providing educational information to helping them understand their insurance coverage and identify potential financial assistance options. For more information, patients and healthcare professionals can call 1-800-282-7630.

Discussions with global health authorities regarding the MONALEESA-3 and MONALEESA-7 data are ongoing.

Latest News

Johnson & Johnson Names Dr. Nadja West, Retired United States Army Lieutenant General and Former United States Army Surgeon General to its Board of Directors

Originally published on jnj.com. Johnson & Johnson is a DiversityInc Hall of Fame company. Johnson & Johnson announced today that Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General has been appointed to its Board of Directors. “I am pleased to welcome Dr….

AT&T

AT&T Celebrates the Aspire Accelerator Class of 2020

Originally published on ATT.com. AT&T is a DiversityInc Hall of Fame company. Immersed Games and Social Cipher win annual “Pitches with Purpose” competition; each receive $25K award Yesterday, eight education technology companies graduated from the Aspire Accelerator and competed in an all-virtual “Shark Tank”-style “Pitches with Purpose” for two $25,000 prizes…

NelsonHall Recognizes ADP as a Leader in the Efficiency Focused NEAT Graph for Cloud-Based HR Transformation Services 2020 Evaluation

Originally published on ADP.com. ADP ranked No. 4 on The DiversityInc Top 50 Companies for Diversity list in 2020. ADP acknowledged for improving processes, lowering costs and providing better decision-making driven by analytics and automation for clients Industry analyst firm NelsonHall has positioned ADP as a Leader in its Efficiency Focused…

Child studying to improve test scores

Test Scores Drop Dramatically for Black, Hispanic and Poor Children Due to COVID-19; Nasdaq Moves to Require Diversity for Listed Companies; and More

Math and reading test scores have dropped dramatically for Black, Hispanic and poor children due to COVID-19, new study warns. Results of lockdowns, home-schooling, and Zoom classrooms as a result of COVID-19 are starting to come in, and the numbers aren’t good. According to a review of more than 4…

Trump

The Platinum Plan: How Trump Increased His Black Vote by 50% and What We Can Learn From It

Do you know what Donald Trump’s “Platinum Plan” was? Most Black people I know do. Most white people have never heard of it. The plan — a two-page document released just weeks before the 2020 election — details the four pillars of Trump’s commitment to Black Americans (Opportunity, Security, Prosperity…

Hershey Statement on Cocoa Sustainability and Supporting the Living Income Differential

Originally published on thehersheycompany.com. Hershey’s commitment to improving cocoa farmer livelihoods and ensuring a long-term sustainable cocoa supply is unwavering. Solving the many challenges within cocoa production, such as low incomes, poverty, child labor and environmental protection will be possible only through collaboration and cooperation across industry, governments, and civil…